Výsledky vyhledávání - Josep Mallolas
- Zobrazuji výsledky 1 - 20 z 34
- Přejít na další stránku
-
1
-
2
TRIZAL study: switching from successful HAART to Trizivir<sup>TM</sup> (abacavir‐lamivudine‐zidovudine combination tablet): 48 weeks efficacy, safety and adherence results Autor Christine Katlama, S. Fenske, Brian Gazzard, Adriano Lazzarin, Nathan Clumeck, Josep Mallolas, Alain Lafeuillade, J‐P Mamet, L Beauvais
Vydáno 2003Artigo -
3
Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine Autor Ulrich A. Walker, Jochen Bäuerle, Montse Laguno, Javier Murillas, Stefan Mauss, G Schmutz, Bernhard Setzer, Rosa Miquel, José M. Gatell, Josep Mallolas
Vydáno 2004Artigo -
4
Impact of Switching from Human Immunodeficiency Virus Type 1 Protease Inhibitors to Efavirenz in Successfully Treated Adults with Lipodystrophy Autor Estebán Martínez, Miguel A García-Viejo, José-Luís Blanco, Luís Bianchi, E Buira, Ignacio Conget, Roser Casamitjana, Josep Mallolas, Josep M. Gatell
Vydáno 2000Artigo -
5
Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction Autor Estebán Martínez, María Larrousse, Daniel Podzamczer, Ignacio Pérez, Félix Gutiérrez, Montserrat Loncà, Patricia Barragán, R. Deulofeu, Roser Casamitjana, Josep Mallolas, Judit Pich, José M. Gatell
Vydáno 2010Artigo -
6
Cytomegalovirus infection in HIV-infected patients in the era of combination antiretroviral therapy Autor Rafael Perelló, Andrea Vergara, Ester Monclús, Sònia Jiménez, Marta Montero, Narcı́s Saubi, Asunción Moreno, Yoshiki Eto, Alexy Inciarte, Josep Mallolas, Estebán Martínez, María Ángeles Marcos
Vydáno 2019Artigo -
7
Preliminary Data of a Prospective Study on Neuropsychiatric Side Effects After Initiation of Efavirenz Autor Jordi Blanch, Estebán Martínez, Araceli Rousaud, José-Luís Blanco, Miguel-Ángel García-Viejo, Josep‐Maria Peri, Josep Mallolas, Elisa de Lazzari, Joan de Pablo, Josep M. Gatell
Vydáno 2001Artigo -
8
A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care Autor Christopher McGowan, Ali Monis, Bruce R. Bacon, Josep Mallolas, Fernando Lopes Gonçales, Ioannis Goulis, Fred Poordad, Nezam H. Afdhal, Stefan Zeuzem, Teerha Piratvisuth, Patrick Marcellin, Michael Fried
Vydáno 2013Artigo -
9
Incidence and causes of death in HIV‐infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the... Autor Estebán Martínez, Ana Milinkovic, E Buira, Elisa de Lazzari, Agathe León, María Larrousse, Montserrat Loncà, Montserrat Laguno, J.A. Sirgo Blanco, Josep Mallolas, Felipe García, JM Miró, JM Gatell
Vydáno 2007Artigo -
10
Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis... Autor Juan Berenguer, J. Alvarez-Pellicer, Pilar Miralles Martín, José López‐Aldeguer, Miguel Ángel Von-Wichmann, Carmen Quereda, Josep Mallolas, José Sanz, Cristina Tural, José M. Bellón, Juan González‐García
Vydáno 2009Artigo -
11
Differences between <scp>HIV</scp>‐infected and uninfected adults in the contributions of smoking, diabetes and hypertension to acute coronary syndrome: two parallel case–control s... Autor María Dolores Calvo Sánchez, Rafel Perelló, Ignacio Pérez, M. G. Mateo, Mireia Junyent, Montserrat Laguno, JL Blanco, Maria Martínez‐Rebollar, María S. Guillem, Josep Mallolas, JM Gatell, Peré Domingo, Estebán Martínez
Vydáno 2012Artigo -
12
Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts<sup>*</sup> Autor Elisa de Lazzari, Agathe León, JA Schoenenberger Arnaiz, Estebán Martínez, Hernando Knobel, Eugènia Negredo, Bonaventura Clotet, Joan Montaner, Stephen P. Storfer, M.A. Asenjo, Josep Mallolas, JM Miró, JM Gatell
Vydáno 2008Revisão -
13
Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression Autor Jhon Rojas, José Luís Blanco, María Ángeles Marcos, Montserrat Loncà, Amparo Tricas, Laura Alicia Hernández Moreno, Ana González-Cordón, Berta Torres, Josep Mallolas, Féderico García, José M. Gatell, Estebán Martínez
Vydáno 2016Artigo -
14
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial Autor Margaret Johnson, Princy Kumar, Jean‐Michel Molina, Giuliano Rizzardini, Pedro Cahn, Markus Bickel, Josep Mallolas, Yan Zhou, Cristiana Morais, Sushma Kumar, Peter Sklar, George J. Hanna, Carey Hwang, Wayne Greaves
Vydáno 2019Artigo -
15
Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy Autor Anna Suy, Estebán Martínez, Oriol Coll, Montserrat Loncà, Montse Palacio, Elisa de Lazzari, María Larrousse, Ana Milinkovic, Sandra Hernández, José Luís Blanco, Josep Mallolas, Agathe León, Juan A. Vanrell, José M. Gatell
Vydáno 2005Artigo -
16
Clinical Course and Prognostic Factors of Progressive Multifocal Leukoencephalopathy in Patients Treated with Highly Active Antiretroviral Therapy Autor Juan Berenguer, Pilar Miralles, Julio Arrizabalaga, Esteban Ribera, Fernando Dronda, Josu Baraia‐Etxaburu, Peré Domingo, Manuel Márquez, Francisco Rodríguez-Arrondo, Fernando Ballester Laguna, Rafael Rubio, Jose Lacruz Rodrigo, Josep Mallolas, Verónica de Miguel
Vydáno 2003Artigo -
17
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy Autor Estebán Martínez, José Luís Blanco, Juan A. Arnaiz, José B Pérez-Cuevas, Amanda Mocroft, Anna Cruceta, María Ángeles Marcos, Ana Milinkovic, Miguel A García-Viejo, Josep Mallolas, Xavier Carné, Andrew Phillips, José M. Gatell
Vydáno 2001Artigo -
18
Long-Term CD4+ T-Cell Response to Highly Active Antiretroviral Therapy According to Baseline CD4+ T-Cell Count Autor Felipe Garc a, Elisa de Lazzari, Montserrat Plana, Pedro Castro, Gabriel Mestre, Meritxell Nomdedéu, Emilio Fumero, Esteban Mart nez, Josep Mallolas, Jos L. Blanco, Jos M. Mir, Tom s Pumarola, Teresa Gallart, Jos M. Gatell
Vydáno 2004Artigo -
19
The Impact of Reducing Stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients Autor Ana Milinkovic, Estebán Martínez, Sònia López, Elisa de Lazzari, Òscar Miró, Sergi Vidal, José Luís Blanco, Glòria Garrabou, Montserrat Laguno, Joan Albert Arnáiz, Agathe León, María Larrousse, Montserrat Loncà, Josep Mallolas, José M. Gatell
Vydáno 2007Artigo -
20
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients Autor Montserrat Laguno, Javier Murillas, José Luís Blanco, Estebán Martínez, Rosa Miquel, José M. Sánchez–Tapias, Xavier Bargalló, Ángeles García‐Criado, Elisa de Lazzari, María Larrousse, Agathe León, Montserrat Loncà, Ana Milinkovic, Josep M. Gatell, Josep Mallolas
Vydáno 2004Artigo
Vyhledávací nástroje:
Související témata
Medicine
Internal medicine
Human immunodeficiency virus (HIV)
Viral load
Antiretroviral therapy
Immunology
Gastroenterology
Virology
Virus
Confidence interval
Pharmacology
Hepatitis B virus
Discontinuation
Disease
Environmental health
Lamivudine
Population
Adverse effect
Cohort
Hepatitis C
Incidence (geometry)
Optics
Physics
Retrospective cohort study
Abacavir
Biology
Coronavirus disease 2019 (COVID-19)
Family medicine
Hepatitis C virus
Infectious disease (medical specialty)